๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview

โœ Scribed by Michael Hubalek; Christine Brantner; Christian Marth

Publisher
Springer Vienna
Year
2010
Tongue
German
Weight
130 KB
Volume
160
Category
Article
ISSN
0043-5341

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combined endocrine effects of LHRH agoni
Combined endocrine effects of LHRH agonist (Zoladexยฎ) and tamoxifen (Nolvadexยฎ) therapy in premenopausal women with breast cancer
โœ Mr J. F. R. Robertson; K. J. Walker; R. I. Nicholson; R. W. Blamey ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 355 KB ๐Ÿ‘ 2 views

Abstract In premenopausal women with breast cancer, the use of the luteinizing hormone releasing hormone agonist, goserelin, results in the production of serum levels of oestradiol equivalent to those after surgical oรถphorectomy or in postmenopausal women. The standard first line hormonal treatment

Completion of adjuvant radiation therapy
Completion of adjuvant radiation therapy among women with breast cancer
โœ Tomasz P. Srokowski; Shenying Fang; Zhigang Duan; Thomas A. Buchholz; Gabriel N. ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 98 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Optimal treatment for breast cancer often involves lengthy multimodality care including 5 to 6 weeks of radiotherapy, but few studies have evaluated adherence to radiotherapy outside the context of a therapeutic clinical trial. ## METHODS. Using a SEERโ€Medicare databas